by Elizabeth Kissling | Sep 19, 2010 | New Research, Pharmaceutical, PMDD, PMS
Some of you may recall that in my book, Capitalizing on the Curse, I argued that the addition of PMDD to the DSM-IV and the re-branding of fluoxetine HCI as Sarafem are linked. It was no coincidence that pharmaceutical manufacturer Eli Lilly sought a unique FDA...